Hematopoietic Stem Cell Transplant Survival Rates: How to Read Them as of 2026

There is no separate survival statistic specifically for hematopoietic stem cell transplant alone. The closest nationwide reference figure is Korea's 5-year relative survival rate for leukemia, 55.7% (National Cancer Registry Statistics, 2019–2023). However, this figure combines both acute and chronic cases, and the actual benefit of transplant varies greatly depending on subtype and risk group.

Key Takeaways

• Korea's 5-year relative survival rate for leukemia is 55.7% (National Cancer Registry Statistics 2019–2023, National Cancer Information Center), and this is a nationwide figure, not the outcome of any single hospital.
• For reference, the U.S. SEER (2016–2022) 5-year relative survival rate for leukemia is 68.6%, but simple comparison is difficult because the mix of acute vs. chronic cases and the age distribution at diagnosis differ.
• How much a transplant improves survival cannot be captured in a single number — for conditions such as high-risk acute leukemia, where chemotherapy alone carries a high relapse risk, allogeneic transplant is considered as a way to reduce relapse.
• Allogeneic transplant requires management of graft-versus-host disease, while autologous transplant carries no rejection risk but leaves some possibility of residual cancer cells being reinfused — so the risk-benefit profile differs between the two.
• Survival rates are population averages and are not numbers that predict an individual patient's outcome.

How does hematopoietic stem cell transplant affect survival?

• Transplant aims for two effects at once: high-dose chemotherapy (conditioning regimen) eliminates as much residual cancer in the bone marrow as possible, and in allogeneic transplant, the donor's immune cells additionally attack any remaining cancer cells.
• Together, these two effects make transplant a way to lower relapse risk in conditions such as high-risk acute leukemia, where chemotherapy alone carries a high risk of relapse.
• However, the same immune mechanism can attack the patient's skin, gut, and liver, causing graft-versus-host disease, which is managed with immunosuppressants to balance benefit against burden.
• Autologous transplant is more common for multiple myeloma and relapsed lymphoma, while allogeneic transplant is more common for high-risk acute leukemia; which option is more advantageous for survival depends on the type of disease and risk group.

What is the process for checking outcomes after transplant?

• Step 1: In the 1–2 weeks after arrival, staging tests are performed along with checks of heart, lung, liver, and kidney function, infection screening, and — for allogeneic transplant — donor HLA tissue-typing.
• Step 2: The patient receives about one week of conditioning chemotherapy to clear out the diseased marrow.
• Step 3: On the scheduled day, hematopoietic stem cells are infused intravenously. This is not a surgical procedure but closer to a blood transfusion.
• Step 4: The patient stays in a sterile isolation room for 2–4 weeks until engraftment, during which fever, mucositis, and low blood counts are managed with transfusions and antibiotics.
• Step 5: Even after engraftment is confirmed, patients do not return home immediately; they continue outpatient follow-up within walking distance of the hospital. For allogeneic transplant, monitoring for graft-versus-host disease and infection often continues until around 100 days post-transplant.

FAQ — Why are survival figures quoted differently for different transplants?

This is because the clinical course varies greatly by type of blood cancer. Chronic myeloid leukemia can often be controlled long-term with oral targeted therapy, while for acute leukemia and multiple myeloma, subtype and whether transplant is performed greatly affect the course. So the overall leukemia figure of 55.7% cannot be directly applied to any individual patient's disease — whether transplant is needed for your specific risk group, and what effect to expect, should be determined through consultation with your medical team.

FAQ — Which offers better survival, allogeneic or autologous transplant?

It depends on the disease. For conditions like acute leukemia, where chemotherapy alone carries a high relapse risk, allogeneic transplant is considered as a way to lower relapse — but it requires management of graft-versus-host disease. For multiple myeloma and relapsed lymphoma, autologous transplant is more common; it proceeds without rejection risk, but some possibility of reinfusing residual cancer cells remains. Which option to choose is decided by the medical team based on disease type, age, and organ function.

Sources and Notes

• This article was written based on notes on blood cancer and hematopoietic stem cell transplantation (National Cancer Registry Statistics 2019–2023, National Cancer Information Center; SEER 2016–2022; NCCN Guidelines for Patients; Medical Korea).
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on an individual's condition. Accurate diagnosis and treatment decisions must be made in consultation with a medical professional.